Pre-Eclampsia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pre-Eclampsia – Drugs In Development, 2024 report and make more profitable business decisions.
Hypertension during pregnancy is termed pre-eclampsia. It generally occurs during the second trimester or after giving birth. Although there is no exact cause but stress, abnormal placentation is believed to lead to pre-eclampsia. Obesity, underlying diseased conditions hypertension, diabetes, kidney disease, or genetic causes may also lead to this. When pathologically examined high levels of protein in the urine (proteinuria), renal insufficiency, and thrombocytopenia are observed. Headache, SOB, blurred vision, nausea and vomiting, pain in the abdomen are common complaints. Premature delivery of the baby is considered in emergency cases and in mild to moderate cases blood pressure management with beta-blockers such as labetalol, or calcium channel blockers nifedipine given.
The Pre-Eclampsia drugs in development market research report provide comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pre-Eclampsia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pre-Eclampsia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pre-Eclampsia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pre-Eclampsia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aggamin LLCArtemis Biotechnologies LLC
Comanche Biopharma Corp
Cts Biopharma LLC
Dilafor AB
Ferring International Center SA
Gmax Biopharm LLC
Larix Bioscience LLC
Shenzhen Evergreen Therapeutics Co Ltd
UMass Chan Medical School
Vicore Pharma AB
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pre-Eclampsia reports